Health and Healthcare

Arbutus Biopharma : ABUS

ABUS

Stock Data

$4.32

$0.12 (2.86%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Arbutus Biopharma Corp is a biopharmaceutical company focused on developing treatments for chronic Hepatitis B virus (HBV) infection and other coronaviruses, including COVID-19. With a product pipeline that includes a subcutaneously-delivered RNAi therapeutic and an oral HBV RNA destabilizer, Arbutus aims to suppress HBV antigens and reawaken the immune system. The company, which was previously known as Tekmira Pharmaceuticals, collaborates with various pharmaceutical firms and is based in Warminster, Pennsylvania.

All Arbutus Biopharma Articles

4 Articles

Jon C. Ogg | Sep 2, 2020 at 7:27 PM EDT

As CDC Issues Notice, Stock Market Bets Which Company Gets First COVID-19 Vaccine FDA Approval

America and the rest of the world is getting ready for a vaccine that will help protect public health against…

Jon C. Ogg | Sep 1, 2020 at 8:46 AM EDT

3 COVID-19 Vaccine Trials Are Now in Phase 3, With More on the Way

Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but…

Chris Lange | Jul 24, 2020 at 11:25 AM EDT

Moderna’s Pain Is Arbutus’s Gain in COVID-19 Patent Ruling

Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute…

Chris Lange | May 19, 2020 at 10:51 AM EDT

Why One Analyst Is Doubling Its Target After Hepatitis B Study

Arbutus Biopharma shares jumped on Tuesday after the company reported positive data from its early-stage clinical trial in patients with…